SCHEMBL2008203

SCHEMBL2008203

CCOC(=O)COc1ccc(C(=O)CN)c(O)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.47
CASP7 P55210 1/20 0.47
CASP9 P55211 1/20 0.47
ABCB1 P08183 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
ESR1 P03372 1/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HSD17B10 Q99714 3/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
HPGD P15428 2/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GRM2 Q14416 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008184 0.88 CASP3 (0.46) CASP3CASP7CASP9ABCB1NPSR1
SCHEMBL2009899 0.88 ALDH1A1 (0.51) CASP3CASP7CASP9ABCB1NPSR1
SCHEMBL2012527 0.87 CASP3 (0.45) CASP3CASP7CASP9ABCB1NPSR1
SCHEMBL2013759 0.86 CASP3 (0.47) CASP3CASP7CASP9ABCB1NPSR1
SCHEMBL2010807 0.85 SMN1; SMN2 (0.57) CASP3CASP7CASP9ABCB1MEN1
SCHEMBL2009189 0.85 PPARG (0.48) CASP3CASP7CASP9ABCB1ESR1
SCHEMBL2010092 0.85 MAPT (0.58) CASP3CASP7CASP9ABCB1NPSR1
SCHEMBL2007749 0.84 CASP3 (0.43) CASP3CASP7CASP9ABCB1NPSR1
SCHEMBL2013912 0.80 HPGD (0.53) CASP3CASP7CASP9ABCB1NPSR1
SCHEMBL28679107 0.79 MAPT (0.45) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 CASP3 4105/4885CASP7 4127/4885CASP9 3233/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 CASP3 4105/4885CASP7 4127/4885CASP9 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.